312 related articles for article (PubMed ID: 15828547)
21. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Ingle JN
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1031s-1036s. PubMed ID: 16467121
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
Prescrire Int; 2005 Jun; 14(77):108-10. PubMed ID: 15984106
[TBL] [Abstract][Full Text] [Related]
23. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Panasci LC
J Clin Oncol; 2001 May; 19(9):2578; author reply 2580-2. PubMed ID: 11331341
[No Abstract] [Full Text] [Related]
24. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL;
J Clin Oncol; 2007 May; 25(15):2006-11. PubMed ID: 17452676
[TBL] [Abstract][Full Text] [Related]
25. A review of the BIG results: the Breast International Group 1-98 trial analyses.
Doughty JC
Breast; 2008 Jan; 17 Suppl 1():S9-S14. PubMed ID: 18279765
[TBL] [Abstract][Full Text] [Related]
26. Anastrozole (Arimidex) vs. tamoxifen for treatment of early breast cancer.
Med Lett Drugs Ther; 2003 Mar; 45(1152):22-3. PubMed ID: 12637893
[No Abstract] [Full Text] [Related]
27. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
28. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
29. Letrozole: advancing hormone therapy in breast cancer.
Lee RJ; Armstrong AC; Wardley AM
Womens Health (Lond); 2012 Nov; 8(6):611-8. PubMed ID: 23181527
[TBL] [Abstract][Full Text] [Related]
30. New developments in the treatment of postmenopausal breast cancer.
Howell A
Trends Endocrinol Metab; 2005 Nov; 16(9):420-8. PubMed ID: 16213745
[TBL] [Abstract][Full Text] [Related]
31. New treatment option for postmenopausal women with early breast cancer.
Expert Rev Anticancer Ther; 2002 Dec; 2(6):617. PubMed ID: 12503198
[No Abstract] [Full Text] [Related]
32. Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
Okunade G; Green AR; Ying M; Agrawal A; Paish EC; Aleskandrany M; Winterbottom L; Hassell K; Morgan DA; Ellis IO; Cheung KL
Crit Rev Oncol Hematol; 2009 Oct; 72(1):76-82. PubMed ID: 19515574
[TBL] [Abstract][Full Text] [Related]
33. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Bruntsch U
MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
[No Abstract] [Full Text] [Related]
34. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
[TBL] [Abstract][Full Text] [Related]
35. Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
Duffy SR; Taylor L
Am J Obstet Gynecol; 2004 Dec; 191(6):1921-7. PubMed ID: 15592273
[TBL] [Abstract][Full Text] [Related]
36. Toremifene and letrozole for advanced breast cancer.
Med Lett Drugs Ther; 1998 Apr; 40(1024):43-5. PubMed ID: 9580744
[No Abstract] [Full Text] [Related]
37. Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.
Altundag K; Altundag O
J Clin Oncol; 2003 Dec; 21(24):4656; author reply 4657. PubMed ID: 14673060
[No Abstract] [Full Text] [Related]
38. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
Gori S; Anastasi P; Marrocolo F
Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
[No Abstract] [Full Text] [Related]
39. Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.
Kaufmann M; Rody A
J Cancer Res Clin Oncol; 2005 Aug; 131(8):487-94. PubMed ID: 15915367
[TBL] [Abstract][Full Text] [Related]
40. Letrozole in breast cancer.
Shahab N
N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]